| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director | Director, 10% Owner | 10% Owner
3 companies
International S.c.a. Artal last filed a Form 4 in November 2024, as Director, 10% Owner at LXRX. The filings on record cover 3 companies. International S.c.a. Artal's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
Our model assigns International S.c.a. Artal a below-average insider score of 47/100, based on 8 past trades. Over a 12-month horizon, 37.5% of those trades were profitable, with an average 12-month return of -6.5%.
At the last filing, the largest reported position was 9,507,990 shares of CAVA. The CAVA filings lean toward selling, a net 22,500,000 shares.
International S.c.a. Artal has 13 Form 4 filings on record from May 2018 to November 2024, across 3 companies: Director at Cava Group (CAVA), 2023–2024; Director, 10% Owner at Lexicon Pharmaceuticals (LXRX), 2020–2024; 10% Owner at Scholar Rock (SRRK), 2018.
The 20 reported transactions were 7 option exercises, 5 open-market sales, 5 open-market purchases and 1 option or other derivative award, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 5 purchases worth about $160.0M and 5 sales worth about $2.4B.
The largest open-market purchase was 27,775,050 shares of LXRX at an average $2.60 on June 5, 2023, about $72.2M. Twelve months later LXRX was down 31%.
The largest open-market sale was 8,000,000 shares of CAVA at an average $134.13 on November 18, 2024, about $1.1B. Twelve months later CAVA was down 67%.
None of the 5 sales since April 2023 was marked as made under a Rule 10b5-1 trading plan.
Shares as reported in the last Form 4 for each company; the most recent is from November 2024. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Nov 18, 2024 | CAVA Cava Group, Inc. | Director | Sell | 8,000,000 | $134.13 | $1,073,040,000.00 | -45.7% | -2.9% | -67.2% | |
| Aug 26, 2024 | CAVA Cava Group, Inc. | Director, 10% Owner | Sell | 6,000,000 | $116.36 | $698,160,000.00 | -25.5% | +13.3% | -46.7% | |
| Jun 5, 2024 | CAVA Cava Group, Inc. | Director, 10% Owner | Sell | 3,000,000 | $87.25 | $261,750,000.00 | -11.3% | +21.6% | -14.9% | |
| Mar 21, 2024 | CAVA Cava Group, Inc. | Director, 10% Owner | Sell | 2,000,000 | $66.25 | $132,500,000.00 | -7.0% | +36.0% | +23.6% | |
| Feb 27, 2024 | CAVA Cava Group, Inc. | Director, 10% Owner | Sell | 3,500,000 | $53.60 | $187,600,000.00 | -10.9% | +45.4% | +74.7% | |
| Jun 5, 2023 | LXRX Lexicon Pharmaceuticals, Inc. | Director, 10% Owner | Buy | 27,775,050 | $2.60 | $72,215,130.00 | +54.6% | -35.4% | -30.7% | |
| Aug 5, 2022 | LXRX Lexicon Pharmaceuticals, Inc. | Director, 10% Owner | Buy | 2,426,070 | $2.50 | $6,065,175.00 | +5.0% | -24.4% | -33.9% | |
| Aug 1, 2022 | LXRX Lexicon Pharmaceuticals, Inc. | Director, 10% Owner | Buy | 16,173,800 | $2.50 | $40,434,500.00 | +50.1% | -9.3% | -18.1% | |
| Dec 16, 2020 | LXRX Lexicon Pharmaceuticals, Inc. | Director, 10% Owner | Buy | 10,937,500 | $3.20 | $35,000,000.00 | +51.3% | - | - | |
| May 29, 2018 | SRRK Scholar Rock Holding Corp | 10% Owner | Buy | 450,000 | $14.00 | $6,300,000.00 | New | - | - |